C5 and paroxysmal nocturnal hemoglobinuria: However, disease manifestations that are related to EVH and mediated by the C3 complement protein may occur in patients receiving C5i therapy; in fact, one study reported that 72% of patients on C5-targeted ECU therapy remained anemic, with 36% of PNH patients receiving ECU requiring one or more transfusion per year [13].